GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025
GeneDx Holdings Corp. - Class A (WGS)
Company Research
Source: Business Wire
Grew fourth quarter 2024 revenues1 to $95.3 millionExpanded fourth quarter 2024 adjusted gross margins1,2 to 70%Generated fourth quarter 2024 adjusted net income2 of $16.8 millionFY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30%GeneDx to host conference call today at 8:30 a.m. ET GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024."The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and genome testing for an ever-growing number of families. Importantly, diagnosing disease earlier with our cost-effective technology means GeneDx can help save the healthcare system valuable dollars,” said Katherine Stueland, President and Chief Executive Officer of GeneDx. “L
Show less
Read more
Impact Snapshot
Event Time:
WGS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WGS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WGS alerts
High impacting GeneDx Holdings Corp. - Class A news events
Weekly update
A roundup of the hottest topics
WGS
News
- GeneDx (NASDAQ:WGS) was given a new $155.00 price target on by analysts at Wells Fargo & Company.MarketBeat
- JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the YearBusiness Wire
- GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Be 40% Below Their Intrinsic Value Estimate [Yahoo! Finance]Yahoo! Finance
- GeneDx (NASDAQ:WGS) had its price target raised by analysts at BTIG Research from $165.00 to $200.00. They now have a "buy" rating on the stock.MarketBeat
- HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTSPR Newswire
WGS
Earnings
- 10/28/25 - Beat
WGS
Sec Filings
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- 12/11/25 - Form 4
- WGS's page on the SEC website